HS-173 25mg 25mg | Purity Not Available
Adooq Bioscience
HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.
More Information Supplier PageHS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.
More Information Supplier PageHS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.
More Information Supplier PageHS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.
More Information Supplier PageTTNPB enhances reprogramming efficiency in chemically induced pluripotent stem cells (CiPSCs).
More Information Supplier PageTTNPB enhances reprogramming efficiency in chemically induced pluripotent stem cells (CiPSCs).
More Information Supplier PageTTNPB enhances reprogramming efficiency in chemically induced pluripotent stem cells (CiPSCs).
More Information Supplier PageTTNPB enhances reprogramming efficiency in chemically induced pluripotent stem cells (CiPSCs).
More Information Supplier PageINCB024360 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities.
More Information Supplier PageHS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.
More Information Supplier PageCO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC).
More Information Supplier Page